A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for Triple Negative Breast Neoplasms
37 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025